Veritas In Silico Inc.(130A) Summary
130A
TSE Growth
Veritas In Silico Inc.
Result
425
JPY
-6
(-1.39%)
Oct 8, 11:29 am JST
2.69
USD
Oct 7, 10:29 pm EDT
PER
ー
PBR
1.97
Yield
ー%
Margin Trading Ratio
ー
PTS
outside of trading hours
429
Oct 8, 10:28 am JST
Stock Price
Oct 8, 2026
Opening
Oct 8, 9:00 am
426
JPY
2.69
USD
Previous Close
Oct 7
431
JPY
2.72
USD
High
Oct 8, 10:28 am
429
JPY
2.71
USD
Low
Oct 8, 11:27 am
421
JPY
2.66
USD
Volume
9,100
Trading Value
4.00M
JPY
0.02M
USD
VWAP
425.23
JPY
2.69
USD
Minimum Trading Value
42,500
JPY
269
USD
Market Capitalization
2.76B
JPY
0.02B
USD
Number of Trades
22
Opening
Oct 8, 10:28 am
429
JPY
Previous Close
Oct 7
ー
JPY
High
Oct 8, 10:28 am
429
JPY
Low
Oct 8, 10:28 am
429
JPY
Volume
100
Trading Value
0.04M
JPY
VWAP
429.00
JPY
Minimum Trading Value
ー
Market Capitalization
ー
Number of Trades
ー
PTS Stock Price
Liquidity & Number of Trades
As of Oct 8, 2026
Liquidity
Liquidity Grade
| Liquidity | Number Of Trades | Distribution |
|---|---|---|
| High | Over 1,000 | 13.9% |
| Slightly-High | 400 to 1,000 | 18.5% |
| Mid | 50 to 400 | 39.0% |
| Slightly-Low | 10 to 50 | 17.6% |
| Low | Less than 10 | 11.0% |
Mid
1-Year Average
204
1-Year High
Jan 19, 2026
7,313
Margin Trading
| Date | Short Interest | Long Margin Positions | Ratio |
|---|---|---|---|
| Oct 2, 2026 | 0 | 276,400 | ー |
| Sep 25, 2026 | 0 | 254,200 | ー |
| Sep 18, 2026 | 0 | 255,100 | ー |
| Sep 11, 2026 | 0 | 257,400 | ー |
| Sep 4, 2026 | 0 | 256,600 | ー |
Similar Stocks
Company Profile
Veritas In Silico operates a platform business for small molecule and nucleic acid drug discovery targeting mRNA.
Sector
Veritas In Silico Inc. is a Japan-based bio-pharmaceutical company. The company develops a platform for small molecule and nucleic acid drug discovery, specializing in targeting mRNA. It focuses on diseases that cannot be addressed by conventional protein-targeted drug discovery approaches. Using their proprietary in silico RNA structure analysis technology, Veritas In Silico has realized a drug discovery approach that targets partial structures on mRNA. This enables the creation of pharmaceuticals that address unmet medical needs. The company collaborates with multiple pharmaceutical companies, promoting joint research based on their drug discovery platform "ibVIS". By targeting mRNA, Veritas In Silico aims to open up new possibilities in the field of drug discovery and development.